临床荟萃 ›› 2022, Vol. 37 ›› Issue (6): 515-518.doi: 10.3969/j.issn.1004-583X.2022.06.006

• 论著 • 上一篇    下一篇

沙利度胺治疗β-地中海贫血外周血miR-223-3p水平变化及临床价值

朱卫健(), 何颖, 黄慕芳, 付社竹, 王小琪, 李志新, 陈丽君, 李小亮   

  1. 珠海市人民医院 暨南大学附属珠海医院 血液风湿科, 广东 珠海 519000
  • 收稿日期:2022-04-23 出版日期:2022-06-20 发布日期:2022-08-05
  • 通讯作者: 朱卫健 E-mail:jjian2003@126.com
  • 基金资助:
    2020年度珠海市医疗卫生科技计划项目-沙利度胺通过miRNA诱导胎儿血红蛋白治疗β-地中度海贫血的机制研究(ZH2202200041HJL)

Change of miR-223-3p level in peripheral blood of β-thalassemia treated with thalidomide and corresponding clinical value

Zhu Weijian(), He Ying, Huang Mufang, Fu Shezhu, Wang Xiaoqi, Li Zhixin, Chen Lijun, Li Xiaoliang   

  1. Department of Hematology and Rheumatology, Zhuhai People's Hospital(Zhuhai hospital affiliated with Jinan University), Zhuhai 519000, China
  • Received:2022-04-23 Online:2022-06-20 Published:2022-08-05
  • Contact: Zhu Weijian E-mail:jjian2003@126.com

摘要:

目的 探讨输血依赖型β-地中海贫血患者沙利度胺治疗前后外周血单个核细胞中miR-223-3p表达水平的变化,并分析与患者血红蛋白浓度(Hb)及胎儿血红蛋白(HbF)水平的关系。方法 收集8例输血依赖型β-地中海贫血患者及8例健康人的外周静脉血5ml,分离外周血单个核细胞,提取细胞总RNA,应用实时定量PCR的方法,检测口服沙利度胺有效的β-地中海贫血患者外周血单个核细胞的miR-223-3p表达水平,分析miR-223-3p与血红蛋白浓度及HbF、红细胞(RBC)、红细胞比容 (Hct)、平均红细胞体积 (MCV)、平均红细胞血红蛋白量(MCH)、血小板(PLT)的相关性。结果 在β-地中海贫血患者外周血单个核细胞中miR-223-3p相对表达量为0.191±0.089,显著高于对照组0.053±0.039(P=0.003),口服沙利度胺后miR-223-3p相对表达量为0.106±0.047(P=0.047),表达量下降,miR-223-3p表达水平与Hb(r=-0.488,P=0.015)、HCT(r=-0.420,P=0.004)水平呈显著负相关。结论 miR-223-3p在输血依赖型β-地中海贫血患者中高表达,口服沙利度胺后miR-223-3p 表达水平下降,沙利度胺可能通过靶向调节miR-223-3p而改善贫血。

关键词: β-地中海贫血, micro-RNA, 沙利度胺, 胎儿血红蛋白

Abstract:

Objective To explore the change level of miR-223-3p in peripheral blood mononuclearcell (PBMC) of patients with transfusion-dependent β thalassemia under thalidomide treatment, and to analyze its correlation with hemoglobin concentration and fetal hemoglobin (HbF). Methods The 5ml peripheral venous blood was collected from 8 patients with transfusion-dependent β thalassemia and 8 healthy subjects, PBMCs were isolated, then total RNA was extracted from the PBMCs. The effective expression level of miR-223-3p in PBMCs of patients with transfusion-dependent β thalassaemia with oral thalidomide were detected by real-time PCR, and the correlations between miR-223-3p and hemoglobin concentration, HbF, red blood cells (RBC), hematocrit (HCT) value, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and platelets (PLT) were analyzed. Results The relative expression level of miR-223-3p in PBMC of β-thalassemia patients was 0.191±0.089, being significantly higher that of the control group at 0.053±0.039(P=0.003), and the relative expression level of miR-223-3p upon oral administration of thalidomide was 0.106±0.047(P=0.047), and the expression quantity decreased. The expression level of miR-223-3p was found inversely correlated with the level of Hb(r=-0.488,P=0.015) and HCT (r=-0.420,P=0.004). Conclusion The miR-223-3p is highly expressed in patients with transfusions dependent β thalassemia, and the expression level of miR-223-3p decreases upon oral administration of thalidomide. Thalidomide may alleviates anemia by targeting the regulation of miR-223-3p, thereby improving the anemia.

Key words: β-thalassemia, micro-RNA, Thalidomide, Haemoglobin F

中图分类号: